Gemphire Therapeutics Inc. (GEMP) SEC Filing 8-K Material Event for the period ending Monday, December 30, 2019

Gemphire Therapeutics Inc.

CIK: 1638287 Ticker: GEMP

View differences made from one to another to evaluate Gemphire Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Gemphire Therapeutics Inc..


Assess how Gemphire Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Gemphire Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: GEMP
CIK: 1638287
Form Type: 8-K Corporate News
Accession Number: 0001104659-19-076916
Submitted to the SEC: Tue Dec 31 2019 2:04:02 AM EST
Accepted by the SEC: Tue Dec 31 2019
Period: Monday, December 30, 2019
Industry: Pharmaceutical Preparations
  1. Accountant Change
  2. Change in Assets
  3. Change in Control
  4. Ending Agreement
  5. Event for Officers
  6. Financial Exhibit
  7. Financial Obligation Increase
  8. New Agreement
  9. Security Holders Change

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: